Emergent BioSolutions Inc. plans to pursue a spin-off of its Biosciences business into a separate, stand-alone publicly-traded company. The spin-off is expected to create two independent public companies with distinct strategic, operational, and development priorities. The new Biosciences company, to be named at a later date, will focus on novel oncology and hematology therapeutics using its core ADAPTIR platform technology in immuno-oncology. Emergent BioSolutions will continue to operate as a ...